Global Cancer Biomarkers Market Size by Cancer Type, Biomarker Type, Application, End User and Region Insight & Forecast to 2034
Overview
The Global Cancer Biomarkers Market was valued at USD 24.22 Billion in 2025 and is projected to reach USD 109.51 Billion by 2034, growing at a CAGR of 18.25% during the forecast period.
Cancer Biomarkers Market Overview:
The Cancer Biomarkers Market consists of products, tests, technologies, and services that identify biological indicators related to cancer. Cancer biomarkers consist of genes, proteins, DNA, RNA, and other variations that are present in blood, tissue, and other biological samples. Cancer biomarkers help physicians to better understand cancer conditions. The Cancer Biomarkers Market provides cancer biomarker tests that diagnose cancer, predict cancer survival, determine appropriate therapy, monitor cancer treatment, and facilitate cancer research activities. The rising emphasis on personalized medicine and precision oncology is stimulating the demand for effective cancer biomarker solutions.
Cancer biomarkers are used to recognize cancer-specific variations. Blood or tumor tissues can be extracted and analyzed using next-generation sequencing, polymerase chain reaction, immunoassays, and other molecular diagnostic instruments. These biomarker tests can identify particular genetic mutations, proteins, and other variations present in a cancer patient. The healthcare and pharmaceutical sectors utilize such technologies for treatment monitoring, biomarker discovery, companion diagnostics, and clinical research activities. The rising incidence of cancer, increasing healthcare expenditures, growing clinical research, and a spike in personalized treatment options are factors that contribute to the regional market growth and expansion.
North America is a leading region for the Cancer Biomarkers Market due to the high-quality healthcare system, advanced cancer research, extensive adoption of precision medicine, and strong investment in diagnostic technologies. The regional market is also segmented by key firms and institutions that specialize in biotechnology, pharmaceuticals, and molecular diagnostics. Prominent companies include Roche, Thermo Fisher Scientific, Illumina, QIAGEN, Agilent Technologies, and Abbott Laboratories, which provide a wide range of products and services for cancer-related biomarker testing and research activities. The market size, market share, market forecast, and market potential are projected to increase due to the rising need for early cancer detection and novel therapeutics, liquid biopsy advances, and companion diagnostics. Molecular diagnostic technologies will continue to fuel the growth of the industry while also providing new investment opportunities.
Cancer Biomarkers Market Growth and Share Analysis
To know about the Research Methodology :- Request Free Sample Report
Cancer Biomarkers Market Dynamics:
Growing cancer awareness to drive market growth:
Cancer biomarkers are widely utilized in personalized medicine, companion diagnostics, and other disease diagnostics, including risk assessment for disease and drug development. During the forecast period of 2026–2034, one of the key factors forecasted to propel the growth of the cancer biomarkers market is the increasing utilization of biomarkers in disease diagnosis.
Rising levels of technical progress for the creation of cancer biomarkers:
The difficulties in identifying and comprehending the roles and interactions of different proteins have been addressed by advances in array and proteomics technologies. These technical developments have greatly streamlined the process of discovering and creating novel cancer biomarkers.
The existence of potential pipeline candidates increase market demand:
The creation of novel biomarkers for the detection and management of cancer is a major focus of many pharmaceutical companies. Many potential candidates are nearing the end of their development cycles and are forecasted to offer the market a significant boost once they are introduced.
Lack of reimbursement policies for testing limiting the market:
The lack of reimbursement policies for biomarker testing in emerging and developed nations is one of the factors that is restricting the demand for these biomarkers globally, despite the rising prevalence of cancer around the world and the growing number of patients needing diagnostic tests. The high cost of cancer diagnosis and treatment in developing nations is another significant issue limiting the market's growth. Due to this, fewer patients are having biomarker testing, and more patients are favoring other inexpensive detection methods.
Technical difficulties with collecting and storing samples:
One of the main problems for service providers is sample collection, which is followed by sample access. These samples must be subjected to strict quality control, and they must be maintained properly to prevent loss. Additionally, several samples are needed for the procedures of risk identification, screening, diagnosis, and monitoring.
Individualized medicine:
For each patient, personalized medicine determines the best course of action. In some areas of personalized medicine, cancer biomarkers are particularly significant. The detection of these disorders is made possible by the consumables used in cancer biomarker testing. Products for cancer biomarker diagnostics are being employed as companion diagnostics for a number of experimental treatments.
Difficulties with cancer biomarker validation:
The process of validating cancer biomarkers involves assessing tests or gauging performance traits like sensitivity, specificity, and reproducibility. The establishment of cancer biomarkers as trustworthy instruments to support development, medical treatment, and investment decisions in biopharma is dependent on validation.
Cancer Biomarkers Market Trends:
Lung cancer is the second most common type of cancer and the main cause of cancer-related deaths for both men and women worldwide. Lung cancer is brought on by the unchecked growth of abnormal cells that multiply in one or both lungs. Although it can occur in nonsmokers, smokers are at a higher risk of developing lung cancer. The length of time and quantity of cigarettes smoked by the patient both enhance the risk of lung cancer. Occupational or environmental exposure to asbestos, certain metals, some organic compounds, radiation, air pollution, and diesel exhaust are other risk factors.
The market's operating companies are forecast to drive the segment's growth through strategic initiatives. For instance, Amgen announced the introduction of Biomarker Assist in April 2021. This program aims to increase patient access to biomarker testing for those with metastatic (stage IV) non-small cell lung cancer (NSCLC). Patients who qualify for Biomarker Assist may be able to save money on biomarker testing. Also, because of the rising incidence of lung cancer worldwide, there would undoubtedly be an increase in the demand for diagnostic tools, which would fuel this market's growth in the years to come.
Cancer Biomarkers Market Segment Analysis:
Based on Cancer Type, The market is divided into breast, prostate, colorectal, cervical, liver, and lung categories based on the kind. In 2025, breast cancer accounted for the largest sector. In 2025, breast, lung, and prostate cancer collectively accounted for more than 46% of total revenue. The two main elements influencing dominance are rising target population bases and rising knowledge of early testing. Lung cancer, on the other hand, is forecasted to experience the fastest growth during the forecast period. The category is expected to rise as more diagnostic tests are developed that focus on EGFR and BRAF mutations, which serve as vital biomarkers for the detection of non-small cell lung cancer.
Based on Application, Cancer biomolecules are used in a number of industries, including medication research, diagnostics, and customized medicine. Because of factors such as the growing development of high specificity and sensitivity biomarker-based oncology tests, diagnostics was the market's primary revenue-generating application. Because of growing interest among healthcare professionals and rising demand, personalized medicine is expected to experience burgeoning growth. Additionally, rising acceptance of companion diagnostic tests for cancer medications are forecasted to support market growth.
Cancer Biomarkers Market Regional Insights
North America is leading region for cancer biomarkers due to the region’s sophisticated healthcare ecosystem, cutting-edge oncology research, and investments into precision medicine and molecular diagnostics. Meanwhile, Europe is also a significant market due to the growing adoption of biomarker-based diagnostics and personalized cancer treatment. The Asia-Pacific region is the fastest-growing market due to the improvement of healthcare infrastructure, oncology-related R&D, and access to high-tech diagnostics. South America and the Middle East & Africa are also promising regions for market expansion due to the growing healthcare ecosystem and investments into high-tech cancer diagnostics.
Cancer Biomarkers Market Competitive Landscape
The main techniques used by these firms to achieve a solid market position include new product development, collaboration agreements with research institutes for the discovery of novel biomarkers, and mergers and acquisitions of small players. Abbott Laboratories, F.Hoffmann-LA Roche Ltd., QIAGEN, Thermo Fisher Scientific Inc., Affymetrix Inc., Illumina Inc., Agilent Technologies, Merck & Co. Inc.
Cancer Biomarkers Market Recent Industry Developments
| Date | Company | Development | Impact |
|---|---|---|---|
| 04 September 2026 | Guardant Health, Inc. | Guardant Health received U.S. FDA approval for its Guardant360 CDx as a companion diagnostic to identify ESR1 mutations in advanced breast cancer patients eligible for camizestrant therapy. | This clearance expands the clinical adoption of liquid biopsy-based comprehensive genomic profiling for biomarker-guided targeted therapies in breast cancer care. |
| 14 August 2026 | Illumina, Inc. | The U.S. FDA granted PMA supplement approval to Illumina's TruSight Oncology Comprehensive assay for an expanded companion diagnostic indication detecting RET alterations in thyroid cancer. | The approval accelerates patient identification for targeted RETEVMO (selpercatinib) therapy using broad next-generation sequencing (NGS) tumor profiling panels. |
| 11 June 2026 | Guardant Health, Inc. | Guardant Health announced FDA approval of Guardant360 CDx as the companion diagnostic for Boehringer Ingelheim’s targeted treatment HERNEXEOS (zongertinib). | The decision enables non-invasive blood testing to identify HER2 (ERBB2) mutation-positive non-small cell lung cancer patients who qualify for precision oncology treatment. |
| 04 July 2025 | Thermo Fisher Scientific Inc. | Thermo Fisher Scientific secured U.S. FDA approval for its Oncomine Dx Express Test on the Ion Torrent Genexus Dx system as a companion diagnostic for ZEGFROVY. | The automated rapid NGS platform delivers actionable tumor genomic profiling in as little as 24 hours to accelerate precision treatment decisions for EGFR exon 20 insertion lung cancer. |
Cancer Biomarkers Market Scope: Inquire before buying
| Global Cancer Biomarkers Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | US $ 24.22 Bn. |
| Forecast Period 2026 to 2034 CAGR: | 18.25% | Market Size in 2034: | US $ 109.51 Bn. |
| Segments Covered: | by Cancer Type | Breast Cancer Lung Cancer Colorectal Cancer Prostate Cancer Others |
|
| by Biomarker Type | Protein Biomarkers Genetic Biomarkers Other Cancer Biomarkers |
||
| by Application | Drug discovery and Development Diagnostics Personalized medicine Others |
||
| by End-user | Pharmaceutical & Biotechnology Companies Diagnostics & Research Laboratories Hospitals & Specialty Clinics Others |
||
Cancer Biomarkers Market by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)
Cancer Biomarkers Market Key Players:
1. Abbott Laboratories
2. F.Hoffmann-LA Roche Ltd.
3. QIAGEN
4. Thermo Fisher Scientific Inc.
5. Affymetrix Inc.
6. Illumina Inc.
7. Agilent Technologies
8. Merck & Co. Inc.
9. Hologic Inc.
10.Sino Biological Inc.
11.Becton, Dickinson and Company
12.PerkinElmer Inc.
13.Bristol-Myers Squibb
14.Bio-Rad Laboratories
15.Eli-Lilly and Company
16.Pfizer Inc.
17.GlaxoSmithKline Plc.
18.Novartis AG
Frequently Asked Questions:
1] What segments are covered in the Global Cancer Biomarkers Market report?
Ans. The segments covered in the Cancer Biomarkers Market report are based on Cancer Type, Biomarkers Type, Application, and End-user.
2] Which region is expected to hold the highest share in the Global Cancer Biomarkers Market?
Ans. North America is expected to hold the highest share in the Cancer Biomarkers Market.
3] What is the market size of the Global Cancer Biomarkers Market by 2034?
Ans. The market size of the Cancer Biomarkers Market by 2034 is expected to reach USD 109.51 Billion.
4] What is the forecast period for the Global Cancer Biomarkers Market?
Ans. The forecast period for the Cancer Biomarkers Market is 2026-2034.
5] What was the market size of the Global Cancer Biomarkers Market in 2025?
Ans. The market size of the Cancer Biomarkers Market in 2025 was valued at USD 24.22 Billion.